Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Novo Nordisk predicts milder growth in 2025 after obesity star Wegovy doubles sales in Q4 Becker’s contributions to the campaign, meanwhile, include Type 2 diabetes-friendly twists on recipes ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk ... obesity and type 2 diabetes”, said Martin Holst Lange, executive vice president for Development at Novo Nordisk.

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...

Lilly isn't alone in this, Danish drugmaker Novo Nordisk - which markets blockbuster weight loss drug Ozempic - too had ...